Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 610 Shares of Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 610 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $145.55, for a total value of $88,785.50. Following the transaction, the chief financial officer now owns 76,468 shares in the company, valued at $11,129,917.40. This trade represents a 0.79 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, April 23rd, Michael Burkes Brophy sold 495 shares of Natera stock. The stock was sold at an average price of $150.74, for a total transaction of $74,616.30.
• On Monday, March 31st, Michael Burkes Brophy sold 2,562 shares of Natera stock. The stock was sold at an average price of $138.41, for a total value of $354,606.42.
• On Monday, March 17th, Michael Burkes Brophy sold 792 shares of Natera stock. The shares were sold at an average price of $146.04, for a total value of $115,663.68.
• On Monday, February 3rd, Michael Burkes Brophy sold 43,502 shares of Natera stock. The stock was sold at an average price of $176.88, for a total value of $7,694,633.76.
• On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The shares were sold at an average price of $165.87, for a total value of $719,046.45.
• On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The stock was sold at an average price of $176.60, for a total transaction of $333,067.60.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The stock was sold at an average price of $161.87, for a total transaction of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The shares were sold at an average price of $171.98, for a total transaction of $162,693.08.

Natera Trading Down 0.4 %

Shares of NTRA stock traded down $0.69 on Friday, hitting $153.79. The stock had a trading volume of 806,949 shares, compared to its average volume of 1,379,927. The company's 50 day moving average price is $147.95 and its 200-day moving average price is $153.34. Natera, Inc. has a 1 year low of $90.88 and a 1 year high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The firm has a market capitalization of $20.79 billion, a P/E ratio of -87.38 and a beta of 1.80.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on NTRA. BTIG Research restated a "buy" rating on shares of Natera in a research report on Friday, February 28th. Morgan Stanley upped their target price on Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Canaccord Genuity Group reiterated a "buy" rating and set a $180.00 price target on shares of Natera in a report on Wednesday, February 26th. Barclays dropped their price objective on shares of Natera from $200.00 to $160.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Finally, Guggenheim lifted their target price on shares of Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat, Natera currently has a consensus rating of "Moderate Buy" and an average price target of $175.76.

Institutional Investors Weigh In On Natera

Several large investors have recently bought and sold shares of NTRA. Price T Rowe Associates Inc. MD lifted its stake in Natera by 134.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after acquiring an additional 3,871,862 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Natera by 43.7% during the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock worth $1,060,836,000 after purchasing an additional 2,036,396 shares in the last quarter. Norges Bank purchased a new position in Natera in the fourth quarter valued at $224,040,000. Raymond James Financial Inc. acquired a new stake in Natera in the fourth quarter valued at $146,419,000. Finally, Vanguard Group Inc. lifted its holdings in Natera by 7.7% during the 4th quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after buying an additional 879,463 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.